Cite
Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies
MLA
Werner Engl, et al. “Tolerability of Subcutaneous Immunoglobulin 20%, Ig20Gly, in Pediatric Patients with Primary Immunodeficiencies.” Immunotherapy, vol. 11, Apr. 2019, pp. 397–406. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ebb29877e1978fbf99f8835c210e9079&authtype=sso&custid=ns315887.
APA
Werner Engl, Kenneth Paris, Beata Derfalvi, László Maródi, Leman Yel, Barbara McCoy, Nicholas Brodszki, I. Hussain, Amy Darter, Michael Borte, Elie Haddad, & Heinz Leibl. (2019). Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies. Immunotherapy, 11, 397–406.
Chicago
Werner Engl, Kenneth Paris, Beata Derfalvi, László Maródi, Leman Yel, Barbara McCoy, Nicholas Brodszki, et al. 2019. “Tolerability of Subcutaneous Immunoglobulin 20%, Ig20Gly, in Pediatric Patients with Primary Immunodeficiencies.” Immunotherapy 11 (April): 397–406. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ebb29877e1978fbf99f8835c210e9079&authtype=sso&custid=ns315887.